Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $120.18 USD
Change Today +0.17 / 0.14%
Volume 215.9K
TFX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

teleflex inc (TFX) Key Developments

Teleflex Incorporated to showcase Advanced Interventional Access Solutions at European Vascular Course

Teleflex Incorporated announced that it will showcase its range of interventional products at the 19th European Vascular Course in Maastricht on March 8 - 10, 2015. During the event, Teleflex will highlight its Arrow chronic hemodialysis catheter portfolio, which offers both split-tip and step-tip catheters for both retrograde and antegrade insertion techniques. The Arrow NextStep Retrograde and Antegrade product family consists of step-tip catheters that can easily be inserted and tunneled using retrograde or antegrade technique, respectively. These step-tip catheters also have the advantage of split-tip high flow characteristics. The step-tip on these catheters is designed for smooth, over-the-wire transitions during insertions and exchanges. The Arrow Cannon II Plus and Arrow Edge products are split-tip catheters that can be tunneled using retrograde or antegrade technique, respectively. Teleflex will also highlight the Arrow GPSCath Balloon Dilatation Catheter, which features VisioValve technology. The Arrow GPSCath Catheter is a specialty two-in-one device that is indicated for percutaneous transluminal angioplasty in the peripheral vasculature, including iliac, femoral, popliteal, infrapopliteal and renal arteries.

Teleflex Incorporated Signs New Agreements with Premier, Inc. for Endomechanical Products, Suture and Trocars

Teleflex Incorporated has announced three new group purchasing agreements with Premier Inc. The new agreements cover Teleflex’s Weck brand of Endomechanical (Ligation and Stapling) products, Deknatel brand of Cardiovascular Suture, and Weck Vista brand of Bladeless Laparoscopic Access Ports. The agreements begin April 1, 2015 and extend through March 31, 2018. The Weck Hem-o-lok Polymer Locking Ligation System is designed to give surgeons confidence in clip security. The unique polymer locking clip provides the assurance of secure ‘cold’ ligation during critical nerve-sparing prostatectomy procedures. Weck Vista Bladeless Laparoscopic Access Ports are designed with an asymmetrical dilating tip to help minimize patient trauma. The broad line of access ports includes differentiated products for open access techniques using either balloon or cone ports.

Teleflex Launches Triple-Lumen PICC with Chlorag+ard Technology

Teleflex Incorporated has launched a triple-lumen ARROW peripherally inserted central catheter, or PICC, with Chlorag+ard Technology. Pressure-injectable ARROW PICCs with Chlorag+ard Technology are the world's first FDA-cleared central venous catheters to significantly reduce the risk of central line-associated bloodstream infections (CLABSI) and PICC-related vessel thrombosis, compared to traditional uncoated catheters. They are also the only PICCs in the IV catheter marketplace that have received FDA 510(k) clearance for both broad-spectrum antimicrobial and antithrombogenic protection. Hospitals and clinicians have increasingly focused on reducing CLABSI and catheter-related vessel thrombosis when inserting PICCs, which are widely used in acute-care and long-term care settings. In addition to CLABSI and thrombosis, the ARROW PICC with Chlorag+ard Technology protects against thrombotic, intraluminal catheter occlusion, the most common non-infectious complication in the long-term use of central lines. Occlusions can delay patient therapy and also require the use of expensive de-clotting agents. Chlorag+ard Technology uses a proprietary process to chemically bond chlorhexidine to both the internal and external surfaces of the catheter. The chlorhexidine-bonded surfaces, which provide a controlled release of the broad-spectrum antimicrobial, are the key to the PICC's antimicrobial and antithrombogenic benefits. The FDA clearance for ARROW PICCs with Chlorag+ard Technology states that these IV catheters provide less thrombus accumulation for at least 30 days. In Vitro data establishes that the device provides 99.99% colonization reduction against gram + and gram - bacteria and fungi for at least 30 days.

Teleflex Incorporated Declares Quarterly Dividend, Payable on March 16, 2015

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of 34 cents ($0.34) per share of common stock. The dividend is payable March 16, 2015 to shareholders of record at the close of business on March 3, 2015.

Teleflex Incorporated Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Teleflex Incorporated reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter 2014, the company’s net revenues were $476.0 million, an increase of 5.7% over $450.54 million for the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter 2014 net revenues increased 9.0% over the prior year period. GAAP diluted earnings per share from continuing operations were $1.10, as compared to $0.78 in the prior year period, an increase of 41.0%. Fourth quarter 2014 adjusted diluted earnings per share from continuing operations were $1.43, as compared to $1.36 in the prior year period, an increase of 5.1%. Income from continuing operations before interest and taxes was $69,155,000 compared to $54,064,000 a year ago. Income from continuing operations before taxes was $52,559,000 compared to $39,891,000 a year ago. Income from continuing operations was $52,133,000 compared to $35,302,000 a year ago. Net income attributable to common shareholders was $50,638,000 or $1.07 per diluted share, compared to $34,828,000 or $0.77 per diluted share, a year ago. For the full year 2014, the company’s net revenues were $1.84 billion, an increase of 8.5% $1.7 billion over the prior year period. Excluding the impact of foreign currency fluctuations, full year 2014 net revenues increased 8.8% over the prior year period. GAAP diluted earnings per share from continuing operations were $4.10, as compared to $3.46 in the prior year period, an increase of 18.5%. Full year 2014 adjusted diluted earnings per share from continuing operations were $5.74, as compared to $5.03 in the prior year period, an increase of 14.1%. Net debt obligations at December 31, 2014 were $801.4 million compared to $902.7 million at December 31, 2013. Income from continuing operations before interest and taxes was $284,862,000 compared to $233,261,000 a year ago. Income from continuing operations before taxes was $220,110,000 compared to $175,730,000 a year ago. Income from continuing operations was $191,460,000 compared to $152,183,000 a year ago. Net income attributable to common shareholders was $187,679,000 or $4.04 per diluted share, compared to $150,881,000 or $3.45 per diluted share, a year ago. Net cash provided by operating activities from continuing operations was $290,241,000 compared to $231,299,000 a year ago. Expenditures for property, plant and equipment were $67,571,000 compared to $63,580,000 a year ago. Payments for businesses and intangibles acquired, net of cash acquired were $45,777,000 compared to $309,008,000 a year ago. The company provided earnings guidance for the full year of 2015. The company estimates that revenues for full year 2015 will increase 4% to 6% on a constant currency basis. On a GAAP basis, revenues are expected to be flat to down 2% versus the prior year due to the unfavorable impact of foreign currency. The company expects adjusted diluted earnings per share from continuing operations to be between $6.10 and $6.35 for full year 2015, representing an increase of 6.3% to 10.6% over the prior year, which reflects the company expectation of a negative foreign currency headwind of approximately 14%. The company expects full year 2015 GAAP diluted earnings per share from continuing operations to be between $4.22 and $4.37. The company anticipates that its 2015 results will be negatively impacted by foreign exchange movements, the company is committed to implementing operational measures to, in part, mitigate the earnings effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TFX:US $120.18 USD +0.17

TFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ansell Ltd A$27.95 AUD -1.63
Donaldson Co Inc $37.66 USD +0.08
PerkinElmer Inc $50.99 USD -0.44
STERIS Corp $69.14 USD -0.09
West Pharmaceutical Services Inc $55.58 USD -0.53
View Industry Companies
 

Industry Analysis

TFX

Industry Average

Valuation TFX Industry Range
Price/Earnings 29.3x
Price/Sales 2.7x
Price/Book 2.6x
Price/Cash Flow 26.6x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELEFLEX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.